Skip to main content

Advertisement

SpringerLink
Log in

Influence of Waist Circumference on the Metabolic Risk Associated with Impaired Fasting Glucose: Effect of Weight Loss after Gastric Bypass

  • Published:
Obesity Surgery Aims and scope Submit manuscript

Background

Impaired fasting glucose (IFG) is a prediabetic state defined as a fasting plasma glucose (FPG) between 100 and 125 mg/dl. However, individuals in this group do not exhibit the same atherogenic risk.

Methods

The atherogenic profile of subjects with IFG >110 mg/dl (IFG110, n––6) or <110 mg/dl (IFG100, n––31) were compared and the potential differential impact of the waist circumference analyzed. In addition, the same clinical variables were measured in 18 morbidly obese patients (8 males, 10 females; BMI 45.3 ±–.9 kg/m2) before and after weight loss following Roux-en-Y gastric bypass (RYGBP), in order to analyze the influence of the reduction in waist circumference on the improvement of the metabolic risk factors.

Results

Individuals in the IFG110 group showed decreased HDL-cholesterol levels together with an increased total cholesterol to HDL ratio (TC/HDL), accompanied by elevated homocysteine concentrations and white blood cell (WBC) count, and higher waist circumference (P–lt;–.05 for all). Significant correlations between waist circumference and HDL-cholesterol (r– −0.200, P–lt;–.05), TC/HDL (r––.190, P–lt;–.05), WBC count (r––.299, P–lt;–.05), and QUICKI (r– −0.375, P–lt;–.0001) were observed. An almost 3-fold increase in the prevalence of T2DM in subjects in the IFG110 group as compared to IFG100 was observed. In the group of patients who underwent RYGBP, the reduction in waist circumference was significantly associated with the improvement in insulin sensitivity as evidenced by the QUICKI index (r– −0.582, P–lt;–.05) and the reduction in TC/HDL (r––.595, P–lt;–.05).

Conclusion

Waist circumference is related to metabolic risk factors associated with increased levels of IFG. Our data support that individuals with IFG >110 mg/dl and a high waist circumference should undergo an OGTT to exclude the presence of diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Coutinho M, Gerstein HC, Wang Y et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233–0.

    Article  CAS  PubMed  Google Scholar 

  2. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278–01.

    Article  PubMed  Google Scholar 

  3. Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–.

    Article  PubMed  Google Scholar 

  4. Phillips LS, Weintraub WS, Ziemer DC et al. All prediabetes is not the same: metabolic and vascular risks of impaired fasting glucose at 100 versus 110 mg/dl: the Screening for Impaired Glucose Tolerance study 1 (SIGT 1). Diabetes Care 2006; 29: 1405–.

    Article  PubMed  Google Scholar 

  5. Wahrenberg H, Hertel K, Leijonhufvud BM et al. Use of waist circumference to predict insulin resistance: retrospective study. BMJ 2005; 330: 1363–.

    Article  PubMed  Google Scholar 

  6. Seidell JC, Perusse L, Despres JP et al. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. Am J Clin Nutr 2001; 74: 315–1.

    CAS  PubMed  Google Scholar 

  7. Despres JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006; 38: 52–3.

    Article  CAS  PubMed  Google Scholar 

  8. Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y –500 patients: technique and results, with 3–0 month follow-up. Obes Surg 2000; 10: 233–.

    Article  CAS  PubMed  Google Scholar 

  9. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969; 22: 158–1.

    Article  CAS  PubMed  Google Scholar 

  10. Katz A, Nambi SS, Mather K et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402–0.

    Article  CAS  PubMed  Google Scholar 

  11. Gómez-Ambrosi J, Salvador J, Páramo JA et al. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin Biochem 2002; 35: 315–0.

    Article  PubMed  Google Scholar 

  12. Friedewald WT, Levy RI, Fredrickson S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultra-centrifuge. Clin Chem 1972; 18: 499–02.

    CAS  PubMed  Google Scholar 

  13. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237–0.

    Article  CAS  PubMed  Google Scholar 

  14. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093–00.

    Article  CAS  PubMed  Google Scholar 

  15. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481–.

    Article  CAS  PubMed  Google Scholar 

  16. Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep 2006; 8: 100–.

    Article  CAS  PubMed  Google Scholar 

  17. Mertens I, Verrijken A, Michiels JJ et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes 2006; 30: 1308–4.

    Article  CAS  Google Scholar 

  18. Ohshita K, Yamane K, Hanafusa M et al. Elevated white blood cell count in subjects with impaired glucose tolerance. Diabetes Care 2004; 27: 491–.

    Article  PubMed  Google Scholar 

  19. Danesh J, Collins R, Appleby P et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477–2.

    Article  CAS  PubMed  Google Scholar 

  20. Tong PC, Lee KF, So WY et al. White blood cell count is associated with macro- and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care 2004; 27: 216–2.

    Article  PubMed  Google Scholar 

  21. Lee WJ, Wang W, Chen TC et al. Clinical significance of central obesity in laparoscopic bariatric surgery. Obes Surg 2003; 13: 921–.

    Article  PubMed  Google Scholar 

  22. Dixon JB, O’Brien PE. Obesity and the white blood cell count: changes with sustained weight loss. Obes Surg 2006; 16: 251–.

    Article  PubMed  Google Scholar 

  23. Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898–18.

    Article  PubMed  Google Scholar 

  24. Frühbeck G. The adipose tissue as a source of vasoactive factors. Curr Med Chem –Cardiovasc Hematol Agents 2004; 2: 197–08.

    Article  PubMed  Google Scholar 

  25. Matsuzawa Y. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3: 35–2.

    Article  CAS  PubMed  Google Scholar 

  26. Patriti A, Facchiano E, Sanna A et al. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 2004; 14: 840–.

    Article  PubMed  Google Scholar 

  27. Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683–3.

    Article  PubMed  Google Scholar 

  28. Frühbeck G, Diez-Caballero A, Gil MJ et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg 2004; 14: 606–2.

    Article  PubMed  Google Scholar 

  29. Gómez-Ambrosi J, Salvador J, Rotellar F et al. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obes Surg 2006; 16: 262–.

    Article  PubMed  Google Scholar 

  30. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724–7.

    Article  CAS  PubMed  Google Scholar 

  31. Ruano M, Silvestre V, Castro R et al. HOMA, QUICKI and MFfm to measure insulin resistance in morbid obesity. Obes Surg 2006; 16: 549–3.

    Article  CAS  PubMed  Google Scholar 

  32. Torquati A, Lutfi R, Abumrad N et al. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg 2005; 9: 1112–.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Metabolic Research Laboratory, University of Navarra, Irunlarrea 1, 31008, Pamplona, Spain

    Javier Gómez-Ambrosi PhD, Victoria Catalán PhD, Amaia Rodríguez PhD & Gema Frühbeck RNutr, MD, PhD

  2. Department of Surgery, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain

    Carlos Pastor MD, Fernando Rotellar MD & Javier A. Cienfuegos MD, PhD

  3. Department of Endocrinology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain

    Javier Salvador MDPhD, Camilo Silva MD & Gema Frühbeck RNutr, MD, PhD

  4. Department of Biochemistry, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain

    M. Jesús Gil PhD

Authors
  1. Javier Gómez-Ambrosi PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Pastor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Javier Salvador MDPhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Camilo Silva MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fernando Rotellar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Jesús Gil PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Victoria Catalán PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Amaia Rodríguez PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Javier A. Cienfuegos MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gema Frühbeck RNutr, MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier Gómez-Ambrosi PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gómez-Ambrosi, J., Pastor, C., Salvador, J. et al. Influence of Waist Circumference on the Metabolic Risk Associated with Impaired Fasting Glucose: Effect of Weight Loss after Gastric Bypass. OBES SURG 17, 585–591 (2007). https://doi.org/10.1007/s11695-007-9101-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-007-9101-7

Key words

Search

Navigation